CClinicalTrials.gg
RecruitingNCT07839546Updated Sep 24, 2026

Adherence to Clinical Guidelines for Management of Patients With Type 2 Diabetes Mellitus and Obesity

An observational study in Guidelines, Diabetes Mellitus Type 2 and Obesity Type 2 Diabetes Mellitus, sponsored by Aristotle University Of Thessaloniki. Recruiting at 1 site in Greece. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Aristotle University Of Thessaloniki · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Sex
All
01

Study summary

Observational study in physicians regarding their adherence to clinical guidelines (by American Diabetes Association 2025) for the management of type 2 diabetes mellitus and obesity via questionnaire

Read the detailed description

Our study was an anonymous, questionnaire-based, cross-sectional study utilizing frequency-scale questions. The 2025 American Diabetes Association (ADA) 'Standards of Care in Diabetes' served as the guiding framework for this study, specifically Section 8, titled 'Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes' . An online questionnaire was developed, consisting of questions that assessed the frequency of implementing the ADA guidelines, and was distributed to medical personnel nationwide for completion.

02

Conditions studied

  • Guidelines
  • Diabetes Mellitus Type 2
  • Obesity Type 2 Diabetes Mellitus
  • Obesity (BMI > 35) and Diabetes Mellitus

Keywords

  • Guidelines
  • obesity
  • diabetes mellitus type 2
  • physicians
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The target population consisted of physicians in Greece who provide care for patients with type two Diabetes Mellitus and obesity, including General Practitioners, Internal Medicine Specialists, Endocrinologists, Resident Doctors and Rural Service Doctors.

Inclusion criteria

  • Physicians practicing in Greece
  • Physicians treating patients with Diabetes Mellitus type 2 and Obesity

Exclusion criteria

Exclusion Criteria:

  • Non Physicians
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Physicians

    Physicians throughout Greece

    Other: Questionnaire regarding the adherence to American Diabetes Association

Interventions

  • OtherQuestionnaire regarding the adherence to American Diabetes Association

    A questionnaire titled "Physicians' adherence to the current clinical guidelines for the management of patients with type two diabetes mellitus and obesity" was formed, consisting of two sections and 18 closed-ended questions in total. Τhe first part focused on demographics and included four questions, while the second addressed the frequency of adherence to clinical guidelines and consisted of fourteen questions. A 5-point Likert scale, ranging from 'never', 'rarely' (1 - 2 times a month), 'sometimes' (1 - 2 times a week), 'frequently' (3 - 4 times a week) to 'always' (everyday), was used for the 14 questions, aiming to quantify the frequency of implementation. An introductory statement accompanied the questionnaire to provide study details and guarantee anonymous responses.

05

What researchers measure

Primary outcomes

  1. Questionnaire

    A questionnaire titled "Physicians' adherence to the current clinical guidelines for the management of patients with type two diabetes mellitus and obesity" was formed, consisting of two sections and 18 closed-ended questions in total. Τhe first part focused on demographics and included four questions, while the second addressed the frequency of adherence to clinical guidelines and consisted of fourteen questions. A 5-point Likert scale, ranging from 'never', 'rarely' (1 - 2 times a month), 'sometimes' (1 - 2 times a week), 'frequently' (3 - 4 times a week) to 'always' (everyday), was used for the 14 questions, aiming to quantify the frequency of implementation. An introductory statement accompanied the questionnaire to provide study details and guarantee anonymous responses

    Time frame: From start of study (July 2025) until 1 year and half (October 2026)

06

Study locations

1 of 1 sites recruiting
  • Medical School of Aristotle University of Thessaloniki
    Thessaloniki, 54646, Greece
    Recruiting
07

References and documents

Individual participant data

Plan to share: No — Data protection law in Greece and our bioethics committee approval did not allow sharing of data

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07839546
Lead sponsor
Aristotle University Of Thessaloniki
Responsible party
Prof. Triantafyllos Didangelos (Professor of Internal Medicine and Diabetology, Aristotle University Of Thessaloniki) — Principal investigator
First posted
Sep 24, 2026
Start date
Jul 1, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Sep 24, 2026

Study contacts

Triantafyllos Didangelos Prof. MD PhD, Professor
Contact
didang@auth.gr
+302310994776
Eleni Karlafti, Assistant Professor MD PhD
Contact
linakarlafti@hotmail.com
Triantafyllos Didangelos, Prof. MD. PhD
principal investigator · Aristotle University Of Thessaloniki

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion